Translated automatically – community improvements welcome.
Selegiline
Selegiline is a selective and irreversible MAO-B inhibitor that is primarily used for the treatment of Parkinson's disease. By inhibiting MAO-B, it increases the availability of dopamine in the brain and may possess neuroprotective effects. Side effects and interactions with other substances require careful application. It is also being investigated in research for its antidepressant and neuroprotective properties.
Mechanism of Action
- MAO-B inhibitor
Names / Identifiers
IUPAC: Selegiline
Mechanism of Action
Selegiline ist ein selektiver Hemmer des Monoaminoxidase B (MAO-B), der den Abbau von Dopamin im Gehirn hemmt und somit die Dopaminspiegel erhöht.
Effects
Effects described from scientific sources. Individual experiences vary.
Dosage
Individual sensitivity varies. Not a dosage recommendation.
Duration
Risks & Warnings
Warnings
- Severe liver diseases.
- Concurrent use of other MAO inhibitors.
Known Risks
- medium
- Mögliche Nebenwirkungen umfassen Schlaflosigkeit, Schwindel und gastrointestinale Beschwerden.
Safer Use
- Start at a low dose.
- Regular medical check-ups.
Harm reduction tips do not replace medical advice.
Known Interactions
- Avoidance of tyramine-containing foods.
- Interactions with other antidepressants.
This list is not exhaustive. Interactions can have unpredictable effects.
Legal Status
Not legal advice. Status may change.
Receptor Targets
MAO-A
Monoaminoxidase A (MAO-A) ist ein mitochondriales Enzym, das Serotonin, Noradrenalin und Dopamin oxidativ desaminiert. Hemmung führt zu erhöhten Monoamin-Spiegeln und ist die Grundlage der MAO-Hemmer-Therapie bei Depression.
MAO-B
Monoaminoxidase B (MAO-B) ist ein mitochondriales Enzym, das bevorzugt Phenylethylamin, Benzylamin und Dopamin abbaut. Selektive MAO-B-Hemmer werden bei Morbus Parkinson eingesetzt.